Category News

Autobahn Therapeutics Raises $100 Million in Oversubscribed Series C for CNS Disorder Treatments

Autobahn Therapeutics, a biotech firm focused on innovative treatments for neuropsychiatric and neuroimmunologic disorders, has closed an oversubscribed $100 million Series C financing round. The funding was led by Newpath Partners and included new investors Canaan Partners, Monograph Capital, and…

Read MoreAutobahn Therapeutics Raises $100 Million in Oversubscribed Series C for CNS Disorder Treatments

PK MED Secures €1.5M Bpifrance Funding for Cell-Homing Implant in Bone Marrow Transplants

PK MED, a French biotech company established in 2019 by Truffle Capital, has secured €1.5 million in non-dilutive DeepTech financing from Bpifrance. This funding will drive the development of PKM-02, a cutting-edge cell-homing technology designed to improve bone marrow transplantation…

Read MorePK MED Secures €1.5M Bpifrance Funding for Cell-Homing Implant in Bone Marrow Transplants

Gilead and Elton John AIDS Foundation Extend RADIAN Partnership to Tackle HIV in Eastern Europe and Central Asia

Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation (EJAF) have announced a five-year extension of the RADIAN® partnership to address the growing HIV crisis in Eastern Europe and Central Asia (EECA). This partnership aims to support vulnerable…

Read MoreGilead and Elton John AIDS Foundation Extend RADIAN Partnership to Tackle HIV in Eastern Europe and Central Asia

WHO Introduces Innovative Training Course to Empower Parliamentarians in Global Health Security

The World Health Organization has released “The Role of Parliaments and Parliamentarians in Strengthening Health Security Preparedness,” an online training course designed to equip parliamentarians with the knowledge and tools necessary to enhance global health security efforts. The COVID-19 pandemic…

Read MoreWHO Introduces Innovative Training Course to Empower Parliamentarians in Global Health Security

NICE Recommends Ebglyss for Moderate to Severe Atopic Dermatitis Treatment in NHS England for Eligible Adolescents and Adults

Lebrikizumab has been approved for treating moderate-to-severe atopic dermatitis in adolescents (12 years and older) and adults who require systemic therapy. This treatment received approval from the European Commission and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in…

Read MoreNICE Recommends Ebglyss for Moderate to Severe Atopic Dermatitis Treatment in NHS England for Eligible Adolescents and Adults